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1. Introduction 
Systemic lupus erythematosus (SLE) is a generalized autoimmune disease affecting several 
organ systems, characterized by the presence of a vast array of autoantibodies, 
characteristically directed to nuclear antigens (ANA) (Arbuckle et al, 2003, Hahn, 1998, 
Rothman and Isenberg, 2008).  Systemic lupus erythematosus (SLE) is the second most 
common human autoimmune disease affecting between 400 and 1000 per million people 
worldwide (Craft, 2011). 
SLE is caused by the breakdown of tolerance to nuclear self-antigens, which leads to 
activation of autoreactive B cells that produce autoantibodies against self-nucleic acids 
and associated proteins (Lande et al, 2011). These autoantibodies bind self-nucleic acids 
released by dying cells, and form immune complexes that are deposited in different parts 
of the body, leading to detrimental inflammation and tissue damage. A key early event 
that triggers autoimmunity in SLE is the chronic innate activation of plasmacytoid 
dendritic cells (pDCs) to secrete type I interferons (IFNs) (Theofilopoulos et al, 2005; 
Ronnblom et al, 2006; Banchereau and Pascual, 2006). The high levels of type I IFNs 
induce an unabated differentiation of monocytes into dendritic cells that stimulate 
autoreactive B and T cells (Blanco et al, 2001), licensing T cells recognize autoantigens and 
lower the activation threshold of autoreactive B cells (LeBon et al, 2006), thereby 
promoting autoimmunity in SLE. 
Analysis of genes encoding components of the interferon pathway has led to extensive 
support for an association of polymorphic variants of interferon regulatory factor 5 (IRF5) 
with SLE (Bennett et al, 2003; Crow, 2008; Niewold et al,2007;). Recent genomewide 
association studies confirm associations of HLA and STAT4 variants with SLE and also the 
role of PTPN22 (International Consortium, 2008; Rieck et al, 2007; Remmers et al, 2007).  
New reports of genetic SNPs associations include the B-cell-receptor–signaling pathway and 
the mechanisms of adhesion of inflammatory cells to the vasculature (Hom et al, 2008; 
Kozyrev et al, 2008). 
The heterogeneity of clinical manifestations and the disease's unpredictable course (Tan et 
al, 1982) characterized by flares and remissions are very likely a reflection of heterogeneity 
at the origin of disease, with a final common pathway leading to loss of tolerance to nuclear 
antigens. Impaired clearance of immune complexes and apoptotic material and production 
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of autoantibodies have long been recognized as major pathogenic events (Arbuckle et al, 
2003; Rothman and Isenberg, 2008). Apoptotic defects underlie some models of autoimmune 
diseases, and they have been proposed in the pathogenesis of SLE, a prototypic autoimmune 
disorder. 
SLE disease activity can be difficult to monitor, and flares are unpredictable in both 
frequency and severity. Certain clinical laboratory tests, including anti-double-stranded 
DNA antibodies (anti-dsDNA), complement factor levels, and the erythrocyte sedimentation 
rate (ESR) are often measured as potential indicators of disease activity (Ippolito et al, 2011). 
Neutrophils are part of the innate immune response and they have long been suspected  
to play a role in SLE pathogenesis. Nevertheless, their role has not been elucidated  
until very recently. 
In 1948, Hargraves et al. described mature bone marrow neutrophils containing 
intracytoplasmic nuclear material in 25 SLE patients at the Mayo Clinic (Hargraves, 1948). 
This phenomenon, which they called the “LE cell,” helped develop the first diagnostic test 
for this disease (Haserick and Bortz, 1949a).  In 1949, Haserick and Bortz found that plasma 
from 50 to 75% of patients with SLE reproduced the LE cell phenomenon in vitro, with the 
formation of clumps of neutrophils around amorphous masses of nuclear material (Haserick 
and Borts, 1949b). Subsequent reports described the LE factor binding to nuclear 
components, including RNPs and histones. The identification of anti-nuclear antibodies 
(Baugh et al, 1960; Hahn, 1998) later replaced the LE cell as a diagnostic test, and switched 
the focus of lupus research from neutrophils to B cells, which now seems to switch back 
again (see below, NETosis). 
2. Types of cell death 
In human adults, billions of cells die every day as part of the body’s natural processes. Cells 
that become damaged by microbial infection or mechanical stress also die. The cell death 
that occurs in the physiological setting is programmed (Nagata et al, 2010). 
Four different cell-death processes (apoptosis, cornification, necrosis, and autophagy) have 
been officially proposed (Kroemer et al., 2009). In apoptosis, the cell and nuclei condense 
and become fragmented and are engulfed by phagocytes (Kerr et al., 1972). Apoptosis is the 
major death process, but necrosis and autophagic cell death have also been proposed to play 
roles in programmed cell death (Kroemer et al., 2009). Dying cells secrete a “find me” signal, 
and they expose an “eat me” signal on their surface. In response to the “find me” signal, 
macrophages approach the dead cells; they then recognize the “eat me” signal 
(Ravichandran and Lorenz, 2007). 
The machinery used for the engulfment and degradation of the extruded nuclei appears 
similar to that used for the removal of apoptotic cells. Mice deficient in the engulfment of 
apoptotic cells develop SLE-type autoimmune diseases (Hanayama et al., 2004). A defect in the 
degradation of the chromosomal DNA from engulfed cells in mice activates macrophages, 
leading to lethal anemia in embryos and chronic arthritis in adults (Kawane et al., 2001; 
Kawane et al., 2006). These observations indicate that dead cells and the nuclei expelled from 
erythroid precursor cells need to be swiftly cleared for animals to maintain homeostasis. 
2.1 High mobility group box 1 (HMGB1) 
In 1999, K.J. Tracey and colleagues discovered that the abundant chromatin-associated 
protein HMGB1 is secreted by activated macrophages during inflammation, and plays a 
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critical role as a late mediator of lethal endotoxemia and sepsis (Wang et al, 1999). Since this 
initial report, the cytokine activity of HMGB1 has been confirmed by many groups and 
HMGB1 has now been proposed to be a crucial mediator in the pathogenesis of many  
diseases including sepsis, arthritis, and cancer (Erlandsson Harris and Andersson, 2004; 
Dumitriu et al, 2005; Ulloa and Messmer, 2006).   
HMGB1 is an intracellular protein that when present in the extracellular milieu acts as a 
‘‘necrotic marker’’ for the immune system. Recent studies indicate that damaged or necrotic 
cells can release HMGB1 into the extracellular milieu, where it triggers inflammatory 
responses. In contrast to necrosis, cells undergoing programmed cell death or apoptosis 
induce negligible inflammation in the surrounding tissue (Yang et al, 2004), which is 
attributed in part, to the retention of HMGB1 within the apoptotic cells (Kokkola, 2003). 
Indeed, there are two mechanisms for cells to liberate HMGB1 into the  extracellular milieu . 
The first mechanism is a ‘‘passive release’’ of HMGB1 from damaged or necrotic cells: 
extracellular HMGB1 acts as an immune-stimulatory signal that indicates the extent of tissue 
injury (Wang et al, 2004; Yang, 2004), promotes the recruitment of mononuclear cells to clear 
cellular debris and protects against possible infection that often follows trauma (Carriere et 
al, 2007). The second mechanism is an ‘‘active secretion’’ of HMGB1 from immune cells to 
act as a pro-inflammatory cytokine during an immunological challenge. 
IL-33, the most recent addition to the IL-1 family, is a potent proinflammatory cytokine  
that induces production of Th2-associated cytokines IL-4, IL-5, and IL-13, both in vitro and 
in vivo (Schmitz, 2005). Surprisingly, IL-33 has also been described as an abundant 
chromatin associated nuclear factor, which associates with mitotic chromosomes in living 
cells and with interphase chromatin in the nucleus of endothelial cells in vivo (Baekkevold, 
2003). IL-33 therefore constitutes a second example of a chromatin associated cytokine 
(Yamada, 2007). 
2.2 NETosis 
Neutrophils in circulation are directed by cytokines into infected tissues, where they 
encounter invading microbes. This encounter leads to the activation of neutrophils and the 
engulfment of the pathogen into a phagosome. In the phagosome, two events are required 
for antimicrobial activity. First, the presynthesized subunits of the NADPH oxidase 
assemble at the phagosomal membrane and transfer electrons to oxygen to form superoxide 
anions. Second, the granules fuse with the phagosome, discharging antimicrobial peptides 
and enzymes. Together, they are responsible for microbial killing (Klebanoff, 1999). Patients 
with mutations in the NADPH oxidase suffer from chronic granulomatous disease (CGD; 
Heyworth et al., 2003). 
Upon activation, neutrophils release extra cellular traps (neutrophil extracellular traps 
[NETs]; Brinkmann et al., 2004). NETs are composed of chromatin decorated with granular 
proteins, including LL-37, antibiotic peptides, neutrophil peptides and nuclear proteins, e.g. 
histones and HMGB1. These structures bind Gram-positive and -negative bacteria. 
Activated neutrophils initiate a process where first the classical lobulated nuclear 
morphology and the distinction between eu- and hetero-chromatin are lost. Later, all the 
internal membranes disappear, allowing NET components to mix. Finally, NETs emerge 
from the cell as the cytoplasmic membrane is ruptured by a process that is distinct from 
necrosis or apoptosis. This active process is dependent on the generation of ROS by NADPH 
oxidase (Fuchs et al., 2007). With the loss of nuclear and granular membranes, the 
decondensed chromatin comes into direct contact with cytoplasmic and granular 
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components. 120 min after activation the granular marker neutrophil elastase colocalizes 
with chromatin. NETs were detected after PMA activation, but not after incubation with Fas 
antibody (inducing apoptosis) or treatment with S. aureus toxins (inducing necrosis). 
Together, these data indicate that neither apoptosis nor necrosis lead to NET formation, and 
that NET-inducing cell death is different from both apoptosis and necrosis by morphological 
and molecular criteria. A hitherto unknown form of active cell death apparently evolved to 
allow neutrophils to kill microbes post mortem. In this form of cell death, the potent cationic 
antimicrobial peptides and proteins of neutrophils are mixed with chromatin and released 
to form NETs. Interestingly, the generation of ROS by NADPH oxidase is required for 
efficient phagocytic killing, and ROS act as a second messenger to trigger NET formation 
(Lande et al, 2011). 
Importantly, in this form of cell death DNA fragmentation is not activated, allowing the 
chromatin to unfold in the extracellular space. NETs can bind and kill microbes by 
providing a high local concentration of antimicrobial peptides and, at the same time, 
minimize tissue damage by sequestering the noxious granule enzymes (Fuchs et al, 2007). 
Therefore, intact nucleosomes decorated with antimicrobial peptides and nuclear proteins 
may be released in NETosis, whose dysregulation has been postulated to represent a critical 
event in SLE pathogenesis (Craft, 2011). 
3. Cell death as driving force for autoantibodies production 
Phagocytes engulf dead cells, which are recognized as dead by virtue of a characteristic "eat 
me" signal exposed on their surface. Inefficient engulfment of dead cells activates the 
immune system, causing disease (such as SLE). The molecular details of these processes 
have been recently superbly reviewed in Cell  (Nagata, 2010).  
During apoptosis, the asymmetric distribution of phospholipids of the plasma membrane 
gets lost and phosphatidylserine (PS) is translocated to the outer leaflet of the plasma 
membrane. There, PS acts as one major "eat me" signal that ensures efficient recognition and 
uptake of apoptotic cells by phagocytes. PS recognition of activated phagocytes induces the 
secretion of anti-inflammatory cytokines like interleukin-10 (Fadok, 2001). Accumulation of 
dead cells containing nuclear autoantigens in sites of immune selection may provide 
survival signals for autoreactive B-cells.  
The production of antibodies against nuclear structures determines the initiation of chronic 
autoimmunity in systemic lupus erythematosus. Various soluble molecules and biophysical 
properties of the surface of apoptotic cells play significant roles in the appropriate 
recognition and further processing of dying and dead cells. High mobility group box 1 
(HMGB1), C-reactive protein (CRP), and anti-nuclear autoantibodies may  contribute to the 
etiopathogenesis of the disease (Craft, 2011). 
3.1 Autoantibodies in SLE 
Patients with SLE have autoantibodies in their sera against nuclear components (anti-
ribonucleoprotein and anti-DNA antibodies) and sometimes exhibit circulating DNA or 
nucleosomes (Rumore and Steinman, 1990). As unengulfed apoptotic cells are present in the 
germinal centers of the lymph nodes of some SLE patients and macrophages from these 
patients often show a reduced ability to engulf apoptotic cells, a deficiency in the clearance 
of apoptotic cells is proposed to be one of the causes of SLE (Gaipl et al., 2006). Apoptotic 
corps are disposed by phagocytes (Savill, 1994) and show immunosuppressive activity (Voll, 
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1997) and recently are reported to be conducive to generation of B regulatory cells (see 
below) (Gray 2007). 
There is increasing evidence that in systemic lupus erythematosus, nucleosomes, the basic 
chromatin component, represent both a driving immunogen and a major in vivo target for 
antibodies (Casciola-Rosen, 1994; Huggins et al, 1999). Either a disturbed apoptosis or a 
reduced clearance of apoptotic cells by phagocytes may lead to an increased exposure of 
apoptotic nucleosomes protected by HMGB1, to the immune system (Urbonaviciute et al., 
2008). One possible new source of HMGB1-nucleosome complexes is thought to derive from 
NETosis (Lande, 2011; Garcia-Romo, 2011).   
3.2 The Fas/FasL pathway of apoptosis in SLE 
Apoptosis is activated by two pathways, the intrinsic and extrinsic pathways (Ow et al., 
2008). Fas ligand (FasL), tumor necrosis factor (TNF), and TRAIL (TNF-related apoptosis-
inducing ligand) are type II membrane proteins that can activate the extrinsic death 
pathway (Krammer, 2000; Nagata, 1997; Strasser et al., 2009). The binding of FasL to its 
receptor (Fas) induces the formation of the death inducing signaling complex (DISC), 
consisting of Fas, an adaptor protein (FADD), and procaspase 8. Formation of the DISC 
leads to the processing and activation of caspase 8. In both the intrinsic and extrinsic 
pathways, apoptosis is completed by the cleavage of a set of cellular proteins (more than 500 
substrates) by effector caspases (caspases 3 and 7) (Lüthi and Martin, 2007; Timmer and 
Salvesen, 2007). 
Fas is a 43 kDa glycoprotein molecule which is involved in inducing apoptosis in both B and 
T lymphocytes (Singh, 1995). In the murine MRL/lpr/lpr model of systemic lupus 
erythematosus (SLE), the lymphoproliferation (lpr) mutation results in defective 
transcription of the gene that codes for the Fas protein. MRL mice which carry the 
homozygous recessive lpr mutation develop a severe early-onset genetically predetermined 
autoimmune syndrome. Susceptibility to SLE is found to be associated with many genes  
(see Table 1), one of which is APO-1/Fas gene, which is present on chromosome 10 in 
humans (Singh et al, 2009). The APO-1/Fas promoter contains consensus sequences for 
binding of several transcription factors that affect the intensity of Fas expression in cells. The 
mutations in the APO-1/Fas promoter are associated with risk and severity in various 
autoimmune diseases. A decreased rate of apoptosis may possibly be related also to 
elevated levels of soluble Fas (sFas) which can inhibit Fas mediated apoptosis of 
lymphocytes (Kruse et al, 2010).  
 
GENETIC TYPE I IFN (Irf-5, etc) 
TLRs  
(7 to 9) 












Table 1. Possible genetic loci controlling SLE predisposition; they include antigen 
presentation, IFN type-I production by pDCs, activation of autoreactive T and B cells and 
neutrophils, complement cascade and nucleic acid sensing and antibody signalling. 
In overwhelming majority of situations alterations in Fas and FasL expression are viewed in 
frames of Fas-mediated apoptosis (Tinazzi et al, 2009; Nozawa, 1997). Telegina et al. (2008) 
tested a possible involvement of Fas-ligand-mediated "reverse signaling" in the 
pathogenesis of autoimmune diseases such as rheumatoid arthritis (RA) and SLE. The 
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results indicated that high level of sFas in RA patient blood correlates with a high activity of 
disease; in SLE patients with elevated sFas level there was a correlation between sFas 
concentration and tissue and organ damage. In serum sFas is present in oligomeric form 
(Tokano, 1996). Oligomeric sFas demonstrated cytotoxicity in lymphocyte primary culture 
and in transformed cells, while non-toxic recombinant Fas-ligand partially blocked this 
effect (Telegina, 2008). Levels of sFas correlated with the percentages of activated B cells 
defined as CD20(+)CD38(+) cells. Serum levels of sFas correlate with percentages of 
activated B cells but not with that of activated T cells (Bijl, 1998). There is a significant 
correlation between serum concentrations of sFas and serum IL-18 in SLE patients (Sahebari, 
2010). sFas and TNF serum levels are increased in SLE patients (Miret et al, 2001). sFas 
levels seems to be secondary to TNF action, which is enhanced in inflammatory conditions 
such as SLE. Bcl-2 antigen expression and IL-10 serum levels are related to the maintenance 
of SLE activity. These alterations may interfere with the apoptotic process. 
3.2.1 Role of Fas/FasL in SLE 
Fas ligand (FasL), an apoptosis-inducing member of the TNF cytokine family, and its 
receptor Fas are critical for the shutdown of chronic immune responses and prevention of 
autoimmunity. Accordingly, mutations in their genes cause severe lymphadenopathy and 
autoimmune disease in mice and humans. FasL function is regulated by deposition in the 
plasma membrane and metalloprotease-mediated shedding. mFasL is essential for cytotoxic 
activity and constitutes the guardian against lymphadenopathy, autoimmunity and cancer, 
whereas excess sFasL appears to promote autoimmunity (O’Reilly et al., 2009). Lymphocytes 
from aged autoimmune MRL/lpr mice overexpress Fas ligand (FasL), and are cytotoxic 
against Fas+ target cells. This cytotoxic potential is only partly due to FasL, as wild-type 
MRL+/+ lymphocytes are not able to kill Fas+ targets after induction of FasL (Hadj-Slimane 
et al, 2004). IFN alpha, which is increased in SLE, induces overexpression of Fas on 
lymphocyte surface of lpr mice.  
In healthy subjects, more memory than naive T lymphocytes undergo TNF alpha-induced 
apoptosis. By contrast, in patients with SLE, more naive T cells undergo apoptosis with 
TNFalpha (Habib et al, 2009). Enhanced apoptosis of T cells in SLE seems to be independent 
of disease activity or medication. Finally, inhibition experiments showed that apoptosis in 
the presence of TNFalpha was only partly blocked by anti-FasL antibody (Habib, 2009). 
Another study showed that mFas expression levels were significantly higher among SLE 
patients than in healthy controls, and the expression levels had a positive correlation with 
the early apoptosis rate of mononuclear cells in SLE patients (Li et al, 2009).  
Data from several studies demonstrate increasing serum concentrations of the soluble 
molecules sFas and sFasL starting the first days after birth, indicating possibly a gradual 
decrease of apoptosis in early neonatal life (Telegina, 2009). In our study (Turi et al., 2009) 
SLE patients with lower ratios of sFas/sFasL in their sera were of younger age, and had a 
shorter disease duration (as calculated by the time from diagnosis) and also shorter duration 
of therapy and/or less organ damage. This pointed to the association of the index with age, 
which resulted to be strongly correlated with this parameter. Therefore the main variable 
associated with changes of the sFas/sFasL ratio is the age of the subjects.  
Neutrophil apoptosis was significantly increased in patients with juvenile-onset SLE  
as compared with the noninflamed controls (Midgley et al, 2009). Concentrations of 
TRAIL and FasL were significantly increased in sera from patients with juvenile-onset 
SLE, but formation of NETs was not assessed in this study. Finally, it has been reported 
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that SLE serum is capable of inducing apoptosis independent of Fas or TNF-R (Bengtsson 
et al, 2008). 
3.3 Type I Interferons and apoptosis 
Type I IFN (IFN-I) was firstly described in 1957 as a soluble factor responsible for viral 
resistance in vitro. IFN-I can be considered a "director" of protective immune responses 
(Sozzani et al, 2010). The recent finding of the so-called interferon signature in patients 
suffering from different autoimmune diseases has underlined its possible role in the 
pathogenesis of these diseases (Obermoser and Pascual, 2010). Type I IFN has 
immunoregulatory functions by affecting cell proliferation and by inducing 
antiinflammatory responses (Cantaert et al, 2010).  
pDCs, specialized type I IFN producers, significantly enhance autoreactive B cell proliferation, 
autoantibody production, and survival in response to TLR and BCR stimulation (Thibault, 
2009). IFNAR2-/- B cells fail to upregulate nucleic acid-sensing Toll-like receptors TLR7 as 
well as TLR9 expression in response to IFN-I (Ding et al, 2009). In addition, serum levels of 
IFN-alpha increase in parallel with the Fas-dependent cytotoxic potential of lymphocytes from 
MRL/lpr mice as they age (Hadj-Slimane, 2004). MRL/lpr lymphocytes overexpressed mRNA 
for the IFN-alpha receptor (IFNAR-1 and IFNAR-2) chains of the IFN-I receptor and exhibited 
high endogenous levels of phosphorylated Stat1. These data suggest that IFN-alpha plays an 
important role in the SLE-like syndrome occurring in MRL/lpr mice, and link aberrant 
apoptosis caused by FasL to high levels of IFN-I. 
It has been found that type 1 IFNs protect human B cells in culture from spontaneous 
apoptosis and from apoptosis mediated by anti-CD95 agonist, in a dose- and time-
dependant manner (Badr et al, 2010). Such effect on human B cells was totally abrogated by 
blockade of IFNR1 chain. PI3Kδ, Rho-A, NFκB and Bcl-2/BclXL are active downstream of 
IFN receptors and are the major effectors of IFN-I-rescued B cells from apoptosis. 
Furthermore, marked reduction in numbers of CD20 positive B cell in both spleen and 
Peyer’s patches was seen in mice treated with anti-IFNR1. Type I IFNs can stimulate B-cell 
proliferation and differentiation into antibody-secreting plasma cells, and differentiation of 
immature monocytes into antigen presenting dendritic cells. These dendritic cells can 
activate autoreactive lymphocytes and promote autoantibody production (Ding, 2009). 
These functions of type I IFN, coupled with impaired clearance of apoptotic debris in SLE 
patients, promote formation of immune complexes, which are potent inducers of type I IFN 
(Craft, 2011). Inappropriate IFN production and/or an inability to dampen IFN responses 
thus may initiate a positive feedback loop, resulting in perpetuation of the autoimmune 
response. 
4. B cell phenotypes in SLE 
4.1 B lymphocytes development 
Cells that have recently emerged from the bone marrow and have yet to acquire follicular 
markers such as IgD and CD23, but that express very low levels of CD21 and invariably 
express high levels of CD24 and AA4.1, are called T1 or newly formed (NF) B cells (Carsetti, 
2004a). These cells do not require BAFF (B cell–activating factor of the TNF family) for their 
survival (Schneider, 2001), but like all B cells they depend on signals from the BCR for 
survival (Kraus, 2004; Hardy and Hayakawa, 2001). These cells, after emerging from the 
marginal sinus, mature and are drawn into follicles following a CXCL13 gradient (Pillai, 
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2008), initially become transitional follicular B cells, and eventually give rise to at least two 
lineages of B cells, mature FO B cells and MZ B cells. Transitional follicular B cells can be 
subdivided into two distinct categories. NF (newly formed)/T1 (transitional stage 1) B cells 
are believed to differentiate into T2-FP (transitional stage 2-follicular precursors), which 
may either differentiate into mature FO B cells or sequentially into T2-MZP (transitional 
stage 2-MZ B cell precursors) or MZ (marginal zone) B cells (Cariappa and Pillai, 2002).  
Although MZ B cells are defined primarily on the basis of their anatomical localization 
(Martin and Kearney, 2002), the surface expression of a number of markers can also be used 
to characterize these cells. In rodents the only secondary lymphoid organ in which cells 
bearing surface markers characteristic of MZ B cells are normally found is the spleen. Unlike 
follicular B cells that express high levels of IgD and CD23, with either high or low levels of 
IgM, MZ B cells express high levels of IgM and very low levels of IgD and CD23 (Oliver, 
1999). They also express higher levels of CD21 (complement receptor type II), CD1d (an 
MHC class Ib protein linked to the presentation of lipid antigens), CD38 (an ADP-ribosyl 
cyclase), CD9 (a scavenger receptor family protein), and CD25 (the  chain of the IL-2 
receptor) than those on follicular B cells. MZ B cells also express higher levels of B7 proteins 
than do follicular B cells and overall are described as having an “activated” phenotype 
(Oliver, 1997). 
4.1.1 Transitional B cells 
To identify human transitional B cells, two developmentally regulated markers, CD24 and 
CD38, are used in combination with the B-lineage marker CD19. In the peripheral blood, all 
cells of the B lineage (CD19pos) coexpress CD24 and CD38, and, conversely, all non-B cells 
(CD19neg) lack CD24. (Carsetti, 2004b) Three populations of B cells can be discriminated 
based on the relative distribution of CD24 and CD38. The CD24brightCD38neg population 
includes 60% of all B cells and only 2% expressed high levels of both CD24 and CD38 
(CD24brightCD38bright). To distinguish mature from memory B cells, the expression of 
CD27 (a marker of memory cells) can be studied in the three populations. Essentially all 
CD24brightCD38neg cells are memory B cells, and mature B cells correspond to the 
CD24dullCD38pos population. CD24brightCD38bright cells lack CD27 (Carsetti 2004 a, b). 
The analysis of IgM and IgD in the CD24brightCD38bright population shows that 
transitional B cells coexpress IgM and IgD. IL-10 produced by B cells can downregulate 
autoimmune disease in EAE (Fillatreau et al., 2002), collagen-induced arthritis (Mauri et al., 
2003), and inflammatory bowel disease (Mizoguchi et al., 2002). IL-10-deficient (Il10-/-) mice 
also have enhanced hypersensitivity responses (Berg et al., 1995). Neutralizing IL-10 by 
monoclonal antibody (mAb) treatment also enhances these responses, whereas systemic IL-
10 administration reduces them (Ferguson et al., 1994; Schwarz et al., 1994). IL-10 is secreted 
by multiple cell types, including T cells, monocytes, macrophages, mast cells, eosinophils, 
and keratinocytes, and can suppress both Th1 and Th2 polarization (Yanaba, 2008) and 
inhibit macrophage antigen presentation and  proinflammatory cytokine production 
(Asadullah et al., 2003). Thus, B cells and IL-10 play important inhibitory roles during T cell-
mediated inflammatory responses.  
4.1.2 Negative regulation by B cells 
B cells have been recently shown to negatively regulate autoimmunity and inflammation in 
numerous mouse models (Bouaziz, 2008). Mizoguchi and Bhan (2006) were the first to use 
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the term ‘regulatory B cells’ to designate B cells with regulatory properties. 
Suppressor/regulatory B-cell populations have predominantly been identified using diverse 
mouse models of autoimmune diseases, suggesting that autoimmunity itself promotes the 
expansion of these cells as a compensatory mechanism to limit self-directed inflammation. 
Immunological tolerance exemplifies the capacity of the immune system to downmodulate 
host immune responses (Shevach, 2000). Several regulatory T-cell subsets have been 
identified that contribute to immunological tolerance, including naturally arising 
CD4+CD25+Forkhead box protein 3 (FoxP3)+ regulatory T cells (Sakaguchi, 2004) and T-
regulatory type 1 cells that produce high amounts of interleukin-10 (Groux, 1997). B cells are 
generally considered to be positive regulators of immune responses. 
Whether negative regulation is a general property of B cells induced as a consequence of 
normal B-cell activation or whether only a specific subset of B cells posses this property has 
also been unknown. However, it has been recently shown that regulatory B cells are a 
phenotypically unique (CD1dhi CD5+) and rare subset of B cells in the spleens of naı¨ve 
wildtype mice that can significantly influence T-cell activation and some inflammatory 
responses (Yanaba, 2008). This specific subset of regulatory B cells only produces IL-10 and 
is responsible for most IL-10 production by B cells. Other regulatory B-cell subsets that may 
also exist (Mauri and Ehrestein, 2008, Bouaziz, 2008). 
Stimulation of arthritogenic B cells with an agonistic anti-CD40 and collagen generated a 
subset of B cells producing IL-10 (Mauri, 2007).  Transfer of collagen and anti-CD40-
stimulated Bcells to syngeneic immunized mice prevented the induction of arthritis and 
ameliorated established disease. This suppressive effect was associated with a 
downregulation of Th1 cytokines and was dependent upon the release of IL-10 because B 
cells isolated from IL-10- deficient mice stimulated with collagen and anti-CD40 failed to 
suppress disease (Mauri et al, 2007). The engagement of CD40 on B cells is also a principal 
requirement for the generation of Bregs in EAE. Additional in vivo results have shown that 
MZ B cells participate in the suppression of systemic lupus erythematosus (Lenert et al, 
2005). After anti-CD40 treatment an increase of IL-10 production and a decrease of IFN-
gamma release was observed (Mauri, 2000) so it was suggested that the therapeutic effect 
observed after administration of anti-CD40, could have been achieved by redirecting 
pathogenic Th1 type response toward the “protective” Th2 type (Harris et al, 2000). These 
data show that the dialogue between B and T cells during an (auto)-immune response is not 
one sided and demonstrate that B cells have a strong impact in conditioning T cell 
differentiation. 
4.2 Breg phenotype(s) 
Further phenotypical identification showed that the majority of CD19+CD38hiCD24hi B 
cells were also IgMhiIgDhiCD5+CD10+CD20+CD27-CD1dhi (Blair et al, 2010). Interestingly, 
the majority of the CD19+CD5+CD1dhiB cells (71%), previously reported to be regulatory in 
experimental models of inflammation (Matsushita et al., 2008; Yanaba et al., 2008a), are 
contained within the CD24hiCD38hi B cell subset. Co-culture of CD4+ T cells with 
CD19+CD24hiCD38hi B cells significantly suppressed the frequencies of CD4+IFN-+ and 
CD4+TNF-+ T cells. 
The group of Mauri evaluated whether there was a numerical deficit in 
CD19+CD38hiCD24hi B cells in patients with SLE (Blair et al, 2010). The absolute cell 
numbers were not statistically different from controls. In contrast, the numbers of both 
CD19+CD38intCD24int and CD19+CD24hiCD38- B cells were both significantly reduced in 
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SLE patients. These results suggest that the inability of SLE CD19+CD38hiCD24hi B cells to 
suppress the expression of proinflammatory cytokines by CD4+ T cells is unlikely to be due 
to a numerical deficiency. Depleting CD19+ CD38hiCD24hi B cells from PBMCs of healthy 
donors and SLE patients leads to an increased production of inflammatory cytokines such as 
IFN gamma and TNF alpha in healthy donors, suggesting an immunoregulatory effect, but 
this was not observed in SLE patients.  
4.3 Other novel B cell subsets 
A novel subset of  circulating memory B cells with >2-fold higher levels of CD19 [CD19(hi) B 
cells] correlates with long-term adverse outcomes in SLE (Nicholas et al, 2008). These B cells 
do not appear anergic, as they exhibit high basal levels of phosphorylated Syk and ERK1/2, 
signal transduce in response to BCR crosslinking, and can become plasma cells in vitro. 
Autoreactive anti-Smith (Sm) B cells are enriched within this subset.  Quantitative genetic 
variation in CD19 expression correlates with autoimmunity (Sato et al, 2000). CD19(hi) B 
cells have elevated CXCR3 levels and chemotax in response to its ligand CXCL9. Thus, 
CD19(hi) B cells are precursors to anti-self PCs, and identify an SLE patient subset likely to 
experience poor clinical outcomes (Nicholas, 2008). CD19(hi)CD21(lo/neg) B cells of 
uncertain origin are expanded also in common variable immunodeficiency patients with 
autoimmune features (Warnatz et al, 2002).  
B cell functions are under the regulation of B cell antigen receptor (BCR)-induced signals 
and by specialized cell surface coreceptors, or "response regulators", which inform B cells of 
their microenvironment. These response regulators include CD19 and CD22 (Fujimoto and 
Sato, 2007). Importantly, this “CD19/CD22 loop" is significantly related to an autoimmune 
phenotype in mice. Thus, the CD19/CD22 loop may be a potential therapeutic target. 
Regulatory B cells that produce IL-10 are now recognized as an important component of the 
immune system .  
4.4 Role of TLR 7 and 9 
A previously uncharacterized population of B cells has been recently described in aged 
mice, called Age-associated B cells (ABCs), which express integrin αX chain CD11c (Rubtsov 
et al, 2011). This subset is present also in young lupus-prone mice. Upon stimulation, 
CD11c+ B cells secrete autoantibodies and depletion of these cells in vivo leads to reduction 
of autoreactive antibodies. Toll-like receptor 7 (TLR7) is crucial for development of this B 
cell population. A similar population of B cells was observed in elderly women with 
autoimmune disease (Rubtsov et al, 2011). Age-associated mature B cells have been 
described also by Hao et al (2011): they are refractory to BCR and CD40 stimulation but 
respond to TLR9 or TLR7 stimulation and divide maximally upon combined BCR and TLR 
ligation, leading to Ig production and preferential secretion of IL-10. They derive from 
normal mature B cells but have lost the need of BLyS for survival. Finally, they present 
antigen effectively and favor polarization to a TH17 profile. It has been reported four years 
ago (Treml, 2007) that TLR9 stimulates TACI expression in all follicular and marginal zone B 
cells, but only BLyS enhances survival in TLR stimulated B cells. Following the exit from the 
bone marrow, peripheral B cells develop through transitional type 1 (T1) and transitional 
type 2 (T2) B-cell stages. Emerging data suggest that the T2 subset  is the immediate 
precursor of the mature B-cell populations. T2 cells uniquely activate a proliferative, pro-
survival, and differentiation program in response to B-cell antigen receptor (BCR) 
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engagement. The type of signal(s) encountered by T2 cells lead to their differential 
maturation toward the follicular mature versus marginal zone mature B-cell populations (Su 
et al, 2004).  
Among the principal targets of autoantibodies produced in murine SLE are nucleic acid–
protein complexes, such as chromatin and ribonucleoproteins, and the envelope 
glycoprotein gp70 of endogenous retroviruses. The preferential production of these 
autoantibodies is apparently promoted by the presence of genetic abnormalities leading to 
defects in the elimination of apoptotic cells and to an enhanced expression of endogenous 
retroviruses. Moreover, recent studies revealed that the innate receptors TLR7 and TLR9 are 
critically involved in the activation of dendritic cells and autoreactive B cells through the 
recognition of endogenous DNA- or RNA-containing antigens and subsequent development 
of autoimmune responses against nuclear autoantigens (Santiago-Raber et al, 2009). 
Furthermore, the regulation of autoimmune responses against endogenous retroviral gp70 
by TLR7 suggested the implication of endogenous retroviruses in this autoimmune 
response. Clearly, further elucidation of the precise molecular role of TLR7 and TLR9 in the 
development of autoimmune responses will help to develop novel therapeutic strategies 
and targets for SLE (Goeken et al, 2010). 
4.5 Relationship of B1 to Breg cells 
B1 cells constitute a specialized B cell lineage with remarkable properties that include 
spontaneous secretion of immunoglobulin, autoreactive repertoire skewing, focused 
memory characteristics, abnormal receptor signaling, induction of Th17 cell differentiation, 
and production of immunomodulatory IL-10. A particularly exciting issue is the relationship 
of B1 cells to regulatory B cells and the extent to which these cell types may be one and the 
same (Cancro, 2009).   
Colonna-Romano et al (2009) describe the IgD−CD27− double-negative B cell population 
which is increased in the elderly. Most of these cells are IgG+. Evaluation of the telomere 
length and expression of the ABCB1 transporter and anti-apoptotic molecule, Bcl2, shows 
that they have the markers of memory B cells. These cells do not act as antigen presenting 
cells, as indicated by the low levels of CD80 and DR, nor do they express significant levels of 
the CD40 molecule necessary to interact with T lymphocytes through the ligand, CD154 
(Duffau et al, 2010). The authors  hypothesize that these expanded cells are late memory or 
exhausted cells that have down-modulated the expression of CD27.  
It is interesting to note that platelets are the main source of circulating CD154, and they can 
stimulate IFN typeI production from pDCs as well as ligate CD40 on autoreactive B cells 
(Duffau et al, 2010; Craft, 2011).  
5. SLE as the result of defects both in apoptosis control and B cell regulation 
Recent data have emerged to support the role of IFN alpha in both control of cell death and 
regulation of B lymphocyte functions. Two papers (Lande, 2011; Garcia-Romo, 2011) have 
reported the induction of neutrophil changes due to autoantibodies to DNA or RNA in 
immune complexes interacting with FcRIIa as well as TLRs in the presence of inflammatory 
cytokines and IFN type I, resulting in the formation of NETs which represent a type of cell 
death with DNA extrusion and release of antimicrobial peptides and cytolytic enzymes that 
is very effective in defence against bacteria.  
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5.1 Neutrophils, NETosis and B cells 
SLE neutrophils undergo accelerated spontaneous apoptosis in vitro, and SLE sera induce 
the apoptosis of healthy neutrophils, and nuclear material such as DNA and histones, which 
comprises the major structural components of NETs, is released in immunogenic form. The 
inappropriate amplification of this phenomenon in SLE perpetuates B cell stimulation to 
produce anti-DNA and –RNA antibodies, as well as autoantibodies to antibiotic peptides, 
and also, via TLR 7 and 9 interactions, IFN alpha production by pDC (Craft, 2011). IFN in 
turn primes neutrophils for death with NET formation, which makes more immunogenic 
DNA and RNA available to the immune system. Both IFN- and SLE serum up-regulate 
neutrophil TLR7 expression. In addition, sera from ~40% of SLE patients contain TLR7 
ligands in the form of ICs derived from antibodies recognizing small nuclear RNA/RNA 
binding protein complexes. These ICs have been shown to activate pDCs and induce type I 
IFN secretion. Anti-RNP antibodies are not efficient activators of pDCs in vitro, however, 
unless combined with dying cells, which provide the substrate to form ICs that might be 
internalized via FcRIIa. 
Anti-RNP Ig–induced SLE NETosis requires FcRIIa and endosomal TLR7 signaling and 
depends on the formation of ROS. Furthermore, anti-RNP antibodies induce SLE but not 
healthy neutrophils to secrete high levels of LL37 and HMGB1, two endogenous proteins 
that contribute to increase the immunogenicity and uptake of mammalian DNA by pDCs. 
Therefore other sources of immunogenic nuclear material has to be present, and this is 
provided by increased apoptosis, mostly due to Fas/FasL dysregulation, and inefficient 
disposal of IC due to complement and reticulo-endothelial defects.  
5.2 Fas/FasL dysregulation in SLE 
The Fas(CD95) antigen and its ligand (FasL, CD95L) are members of the TNF/TNFR 
families, expressed on the surface of immune and other cell types. They regulate one 
important extrinsic apoptotic pathway, by higher or lower expression and by their splice or 
cleaved soluble variants, sFas and sFasL (Sheriff et al., 2004; Tinazzi et al., 2009). Peripheral 
T cell apoptosis is upregulated in active SLE, in parallel with high expression of both 
membrane-bound and soluble Fas (Silvestris et al., 2003; Hao et al., 2006).  Previous studies 
postulated that sFas down-regulates apoptosis in vitro through its blockade of the FasL of 
cytotoxic cells. This paradox has been examined by Silvestris et al. (2003) and Hao et al. 
(2006), but it is still unresolved. The situation is even more complex since autoantibodies to 
FasL have been detected in sera of SLE patients which contribute to inhibit apoptotic cell 
death of lymphocytes (Suzuki et al., 1998). In our study (Turi et al, 2009) we confirmed that 
though slightly increased values of both sFas and sFasL are found in SLE patients compared 
to normal subjects, a very scattered distribution is observed. No definitive answer to the 
importance of these differences may derive from examining one factor when many 
contribute to the final effect, so we decided to derive and index from the ratio of the values 
of sFas to sFasL, which is about 50 in normal controls. This ratio has been found to be lower 
in younger subjects, being related to age, both in SLE patients and healthy controls. 
Apoptosis resistance is modulated during aging, and the changes in the sFas/sFasL ratio 
may be involved in this phenomenon. As clarified by the study by O’Reilly (2009), sFasL 
does not efficiently mediate Fas-induced apoptosis, therefore its increase in serum equals to 
an additive anti-apoptotic mechanism in conjunction with elevated sFas circulating levels 
and autoantibodies to FasL.  
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Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the 
production of high-titer IgG autoantibodies directed against nuclear autoantigens. Type I 
interferon (IFN-I) has been shown to play an important pathogenic role in this disease. 
Common hypotheses about SLE pathogenesis suggest that environmental triggers, such as 
infectious agents, operate in the context of both susceptibility genes and epigenetic 
modifications, resulting in alterations in antigen presentation, lymphoid signaling, 
apoptosis, and antigen/IC clearance. Decreased numbers of neutrophils, dendritic cells, and 
lymphocytes are common features of SLE. pDCs accumulate at sites of inflammation such as 
the skin and the kidney, where they secrete type I interferon (IFN). Upon exposure to SLE 
serum, healthy monocytes differentiate into mature DCs in an IFN-I–dependent fashion. 
SLE display a type I IFN signature as measured by peripheral blood mononuclear cell 
(PBMC) gene expression profiling. The second most prevalent PBMC transcriptional 
signature corresponds to neutrophil-specific genes, and differential expression of these 
genes correlates with disease activity. Indeed, polymorphisms in genes expressed by 
neutrophils, such as ITGAM/CD11b, rank among the highest in the scale of SLE 
susceptibility. Polymorphisms in genes along the IFN and TLR signaling pathways (that is, 
IRF5, TLR7, IRAK1, STAT4, etc.) could amplify the response of SLE neutrophils to TLR7 
triggering. Polymorphisms affecting thresholds of B cell activation and/or deficient removal 
of ICs might contribute to prolonged neutrophil exposure to activating ICs. Polymorphisms 
in FcgRIIa could affect the internalization and/or endosomal trafficking of SLE-specific ICs 
in neutrophils and pDCs. 
Our review has highlighted some recent aspects of the main points relating to these issues, 
both at the cellular and molecular level, with discussion of the role of NETs formation, TLR 
7/9 signaling, apoptosis increased proneness, and the induction both of autoantibodies and 
IFN-I overproduction. The consequences of these pathogenetic changes are then defined in 
terms of autoantigens presentation, B lymphocyte dysregulation and IC formation with 
organ damage. We mainly studied the alterations occurring at quantitative and functional 
level in the Fas/FasL apoptotic pathway, but also touched upon several other issues such as 
the relationship of newly identified B cell subsets to autoimmunity,  and the role of nuclear 
cytokines in autoantibody stimulation. We believe that the key aspects of SLE pathogenesis 
have now been uncovered, and await the composition of their temporal sequence in a 
unified view of this multifaceted systemic autoimmune disorder. 
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8. Note added in proof 
Since completion of this chapter, a review was published in the section of Clinical 
implications of Basic research of the N Engl J Med (Bosch X (2011). Systemic lupus 
erythematosus and the neutrophil. N Engl J Med 365;8 (Aug.25) 758-60) discussing the work 
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of Lande and Garcia-Romo reviewed here. No mention of HMGB1 is to be found in the 
review, however much emphasis was put on antimicrobial peptides (LL-37, which is also 
implicated in psoriasis) and antagonistic molecules for TLR signalling; the main message 
was on the new therapeutic aspects and the generalization of these findings (of neutrophil 
NETosis as pathogenetic mechanism) to vasculitis with ANCA antibodies.  
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